Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | FAAH | O00519 | 8/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113566 | 0.84 | CYP1A2 (0.73) | CYP1A2FAAHSLC1A3MEN1KMT2A | |
| SCHEMBL9263653 | 0.83 | CYP1A2 (0.57) | CYP1A2FAAHALDH1A1 | |
| SCHEMBL23766626 | 0.80 | CYP1A2 (0.68) | CYP1A2FAAHSLC1A3MEN1KMT2A | |
| SCHEMBL10880459 | 0.80 | CYP1A2 (0.53) | CYP1A2FAAHSIRT2SIRT1 | |
| SCHEMBL28226501 | 0.79 | CYP1A2 (0.66) | CYP1A2FAAHSLC1A3MEN1KMT2A | |
| SCHEMBL20901379 | 0.78 | CYP1A2 (0.61) | CYP1A2FAAHSLC1A3MEN1KMT2A | |
| SCHEMBL8692101 | 0.77 | CYP1A2 (0.64) | CYP1A2FAAHSLC1A3CYP3A4 | |
| SCHEMBL9559459 | 0.75 | CYP1A2 (0.52) | CYP1A2FAAHSIRT2SIRT1SLC1A3 | |
| SCHEMBL29177424 | 0.74 | SYK (0.55) | CYP1A2FAAHSIRT2SIRT1MEN1 | |
| SCHEMBL15619584 | 0.74 | ALDH1A1 (0.54) | MEN1KMT2AGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | LE ROUX DANIELLE MARIE (US) | 2026-03-19 | — | — | US | disclosed |
| US-7071214-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | VIP, GIPR, SLC10A2 | CYP1A2 4011/4885FAAH 1139/4885SIRT2 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.